Hangzhou Alltest Biotech (688606.SH): Net profit for the fiscal year 2024 was 304 million yuan, a year-on-year increase of 68.18%.
Otaibi Biology (688606.SH) released the 2024 annual performance report, reporting that the company achieved operating income of 8...
Hangzhou Alltest Biotech (688606.SH) released its 2024 annual performance report, stating that during the reporting period, the company achieved operating income of 870 million yuan, a year-on-year increase of 15.25%; net profit attributable to the owners of the parent company was 304 million yuan, a year-on-year increase of 68.18%; net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 239 million yuan, a year-on-year increase of 62.92%; basic earnings per share were 3.83 yuan/share.
Related Articles

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


